Clarkston Shares Guest Column on MES For Cell & Gene Therapies
December 20, 2024 | Clarkston Consulting’s Lynette Nazabal was recently featured as a guest columnist with Cell and Gene for her expertise on a MES. She shares perspectives on how MES is essential to the successful commercialization of cell and gene therapy manufacturing processes. Read a short excerpt from the piece below or the full article here.
5 Benefits Of Using MES For Cell & Gene Therapies
“In a previous article, we shared some key considerations for the manufacturing execution system (MES) vendor selection process for life sciences companies. On the rise within life sciences is the fast-moving growth of cell and gene therapy (CGT) companies, which have their own set of unique complexities and challenges in manufacturing. It is valid to question whether these same MES solutions would be right for your CGT manufacturing operation. MES vendors recognize this as well, which is why they have evolved solutions specially designed for CGT manufacturing to help you prepare for commercialization while meeting the unique challenges that accompany these complex processes. Let’s look at how an MES can provide targeted solutions to help mitigate five of the top challenges in the manufacturing and commercialization of cell and gene therapy…”